Collaboration Agreements (Details) - USD ($)	1 Months Ended			12 Months Ended
	Jan. 31, 2022	Sep. 30, 2021	Dec. 31, 2019	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					$ 9,434,000	$ 18,437,000
Collaboration Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					9,434,000	18,437,000
Neurocrine Biosciences [Member] | Collaboration Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					2,310,000	10,167,000
Research and development services					1,938,000	6,452,000
Milestone payments					7,124,000	5,270,000
Neurocrine Biosciences [Member] | Development Services Under the Initial Development Program for the DTCs [Member] | Collaboration Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					372,000	3,715,000
Neurocrine Biosciences [Member] | Research And Development Funding | Collaboration Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development services					$ 1,938,000	6,452,000
Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from upfront fee			$ 50,000,000
Upfront payment received in cash			30,000,000				$ 30,000,000
Upfront payment received in equity investment			$ 20,000,000				20,000,000
Potential milestone payments receivable				$ 1,667,500,000
Percentage of option to co-fund development costs upon achievement of certain milestones				50.00%
Collaborate agreement premium related to equity investment							3,333,000
Transaction price allocated to performance obligations							33,333,000
Milestone Payment Received	$ 15,000,000	$ 10,000,000
Milestone Payment Received in Cash	6,750,000	4,500,000
Milestone Payment Received in Equity Investment	8,250,000	5,500,000
Equity investment measure at fair value	7,876,000	4,730,000
Premium	374,000	770,000
Performance obligation related to milestone	0	0
Revenue	$ 6,750,000	$ 4,500,000
Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member] | Exclusive License to XEN901 and Exclusive License to DTCs [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transaction price allocated to performance obligations							$ 28,807,000
Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member] | Development Services Under the Initial Development Program for the DTCs [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transaction price allocated to performance obligations				$ 5,025,000
Variable consideration allocated to performance obligation				499,000
Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member] | Regulatory Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments receivable				1,067,500,000
Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member] | Sales Based Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments receivable				$ 600,000,000
Pacira BioSciences [Member] | Collaboration Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments						3,000,000
Pacira BioSciences [Member] | Asset Purchase Agreement [Member] | XEN402 [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments						1,000,000
Milestone payment due on initiation of Phase 1b clinical trial						$ 2,000,000